BioCentury
ARTICLE | Clinical News

Bevenopran: Phase III started

July 22, 2013 7:00 AM UTC

Cubist began 3 identical, double-blind, placebo-controlled, U.S. Phase III trials to evaluate 0.25 mg oral bevenopran twice daily for 12 weeks each in about 600 patients receiving opioid therapy for c...